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Abstract
Inflammatory bowel diseases (IBDs) relate to chronic inflammations in different parts 
of the gastrointestinal (GI) tract involving both ulcerative colitis (UC) and Crohn’s dis-
ease (CD). Ulcerative colitis begins in the rectum and extends continuously up the colon. 
Notably, CD may affect any area of the GIT, from the mouth to the anus. Various condi-
tions may influence the genesis of the disease, such as genetics, environment, intestinal 
microbiota and the presence of agents of enteric infections. Experimental models are 
therefore suitably used to investigate the various etiological factors; similarly colitis can 
be induced by genetic modification, cell transfer, spontaneous inflammation and chemi-
cal agents. The objective of this chapter is to present current concept on animal models of 
inflammatory bowel diseases. These models are crucial for the understanding of inflam-
matory bowel diseases, development of alternative treatments and more effective thera-
peutic agents thus contributing to the control of the disease.
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1. Introduction
The immune system has a mechanism of response to tissue injury and antigenic stimuli, 
whose main function is to protect the body. This response is called inflammation. It is char-
acterized by the interaction of several types of cells and signaling molecules, to promote the 
repair of damaged tissue [1, 2]. Despite its protective function, the inflammatory response 
must not be prolonged, since exacerbated inflammation may cause physical loss of function 
in the organ [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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The various manifestations characterized by chronic inflammation include inflammatory 
bowel diseases (IBDs), such as ulcerative colitis (UC) and Crohn’s diseases (CD) [4, 5]. Their 
clinical presentations can be overlapping as well as distinct [6, 7]. UC is generally associated 
to superficial inflammation of the colon mucosa and CD comprises transmural damage that 
may occur in any segment of the gastrointestinal tract (GI) [8].
The IBDs are common among white people between the ages of 20 and 40 years old and the 
second peak of the disease occurs around 55 years of age. The distribution of this disease in 
males and females seems similar, though CD is more frequent in women [9].
The genesis of UC and CD involves multiple factors, such as genetic, environmental, intes-
tinal microbiota and the presence of enteric infections. These factors may affect the immune 
system, by expanding and perpetuating the inflammatory process [10].
The treatment of IBD is considered unsatisfactory, because among other factors, cure may 
not be possible, only remission of the disease and/or treatment of symptoms. Several classes 
of drugs are currently used to treat IBD, such as aminosalicylates, corticosteroids and immu-
nosuppressives [11]. The odds remain that these drugs have many side effects, are expensive 
and lose their efficacy after a certain period of medication [12].
Therefore, concise experimental studies are needed to unravel the etiology and pathophysi-
ological mechanisms of IBD for development of alternative treatments and/or more effec-
tive therapeutic agents to treat patients with ulcerative colitis. Thus, the use of experimental 
animal models becomes essential to elucidate the mechanism(s) involved and accelerate the 
development of a specific and effective therapy.
2. Animal models for inflammatory bowel disease: colitis
The use of animal models is crucial for the investigation of the processes involved in the 
genesis of IBD. Although the development of the disease in animals does not present all the 
mechanisms observed in humans, animal models still are the most effective way to study 
the factors involved in the pathogenesis of BD. It would be difficult to conduct such a study 
in humans. Additionally, the animals are very useful for the assessment of new therapeutic 
approaches [13].
Over time, several experimental models of IBD were developed to conduct experimental stud-
ies, particularly mice and rats. The animal models of intestinal inflammation can be divided 
into four groups according to the type of induction namely: genetic modification, cell transfer, 
spontaneous inflammation and chemical agents [14–16].
The ideal experimental model is characterized by morphological disorders and intestinal 
inflammation, in addition to clinical symptoms, pathophysiology and development of the 
disease similar or equal to human condition IBD [17]. The chapter thus presents animal mod-
els developed for the study of and experimentation on colitis.
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2.1. Genetic modification
The development and use of genetically modified animals have contributed to the investiga-
tion of various issues related to the IBD, and the most frequent are connected to the triggering 
of inflammation through the impairment of various functions such as epithelial barrier and 
detection of bacterial components, signaling of the innate immune response, immune regula-
tion and signaling response to stress [18]. Studies involving the human genome have shown 
the association of more than 160 genes connected to IBD [19] (Table 1).
When the intestinal epithelial barrier is impaired, the intestinal mucosa has contact with bac-
teria from the lumen, which generates the inflammatory responses that will lead to the devel-
opment of IBD. Studies have demonstrated the relationship between CD and certain genes 
involved in the intestinal epithelial barrier function. Animal models that express defects in 
this barrier are discussed and are essential in the investigation of IBD pathogenesis [18].
a. C57BL/6 mouse expressing a dominant negative N-cadherin (NCADΔ)
N-cadherin is a glycoprotein related to epithelial cell adhesion and is essential for normal 
development. Mice with a dominant-negative mutation of N-cadherin developed porous 
regions in the intestinal epithelium and intercellular adhesion disorder, developing trans-
mural inflammation of the jejunum similar to CD at 3 months old. The organization of the 
small intestinal epithelium makes it possible to use chimeric mice, generated from normal 
blastocyts and genetically manipulated embryonic stem cells, to study cadherin function. 
Therefore, embryonic stem cells were transfected with a dominant negative N-cadherin 
mutant (NCADΔ) under the control of promoters active in small intestinal epithelial cells and 
then introduced into C57BL/6 mouse blastocysts [20].
b. FVB mice
FVB mice originated from Swiss syngeneic strains subjected to processes that triggered intol-
erance or sensitivity to histamine. FVB mice were derived from the syngeneic Swiss strains, 
selected from crosses in which progenies received pertussis vaccination and challenged with 
histamine thus developing resistance or sensitivity to it. From this experimental system, two 
strains were selected: one resistant to the histamine factor (HSFR/N) and another sensitive 
(HSFS/N). Within the latter group, in the early 1970s, a group of eight syngeneic generations, 
HSFS/N, carrying Fv-1b alleles and susceptible to the Friend leukemia virus, lineage B, were 
selected. They are good breeders with large progenies and the eggs of the FVB/N lineage 
favor in vitro fertilization procedures since it has a huge pro-nucleus that facilitates DNA 
microinjection and the production of transgenic [21].
c. Muc2 knockout (Muc2−/−) and Muc2 heterozygous (Muc2+/−) mice
The surface of the intestinal mucosa has many components essential for its protection, such as 
MUC2 that has a lubricating function and also provides a protective barrier between the con-
tents of the lumen and mucosal layers. Wild-type (Muc2+/+), Muc2+/− and Muc2−/− littermates 
are mostly used and scores recorded weekly until the age of 16 weeks to obtain a disease 
activity index (DAI). The previously mentioned Muc2−/− mice were backcrossed onto a 129SV 
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(Charles River, Maastricht, The Netherlands) genetic background for nine generations fol-
lowed by intercrosses to breed animals homozygous for the Muc2 disruption. Mice lacking 
this component may develop IBD in the distal colon at approximately 5 weeks of age [22].
d. Intestinal epithelial cell-specific C1galt1−/− (IEC C1galt1−/−) mice
The enzyme β1, 3-galactosyltransferase 1 (C1galt1) is related to the synthesis of O-glycan in 
mucus-producing epithelial cells. The mucus transports a large amount of O-glycan, since 
Mutation Main results References
Dominant-negative mutant N-cadherin Transmural inflammation in the jejunum 
similar to that of patients with CD
[20]
Lack of Muc2 Development of IBD in the distal colon [22]
Specific deletion of C1galt1 in epithelial cells Inflammation in the distal colon [23]
MDR1a gene deleted Development of colitis [24]
Absence of IRE1 α Spontaneous colitis [26]
Nuclear kappa B (NF-kB) deactivated in intestinal 
epithelial cells
Development of colitis with apoptosis of 
epithelial cells
[27, 28]
Specific deletion of type II receptor for TGB-β in 
CD4+-specific T cells and dendritic cells
Spontaneous inflammation in several organs 
and colitis
[29, 30]
Absence of SMAD4 Inflammation through the entire 
gastrointestinal tract
[31]
Absence of IL-2 and deficiency of JAK 3 
(component of IL receptor)
Autoimmune disease with colitis and other 
disorders; spontaneous colitis
[32–34]
Absence of IL-10 and deletion of CRF2-4 
(component of IL-10 receptor)
Spontaneous development of colitis; chronic 
colitis
[38, 39]
Absence of TCR α Spontaneous triggering of colitis [40]
Absence of STAT3 in macrophages and neutrophils Spontaneous onset of colitis [41]
Super expression of STAT4 and immunization with 
DNP-KLH/CFA
Development of transmural colitis [43]
Absence of Gαi2 Triggering of colitis and colorectal cancer [44–46]
Absence of enzyme A20 Inflammation in the intestine and in other 
organs
[47]
Absence of T-bet and T and B cells Onset of colitis similar to UC [48]
Altered levels of TNF-α Development of inflammation of the ileum and 
in the distal colon
[49–51]
Super expression of IL-7 Spontaneous onset of colitis [53]
Absence of Gpx1 and Gpx2 Triggering of colitis and ileitis [54]
Specific deletion of XBP1 factor Development of ileitis [55]
Table 1. Genetic models of colitis.
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this substance forms 80% of the mucus molecular weight. Approximately 30% of the individ-
uals with UC have disorder in O-glycan synthesis. To study the role of O-glycans in intestinal 
tissue, the model was generated by crossing mice with loxP sites flanking C1galt1 (C1galt1f/f 
mice) with an intestinal epithelium-specific Cre-expressing transgenic line (Villin-Cre mice), 
giving rise to animals lacking C1galt1 in the intestinal epithelium, referred to as C1galt1−/− 
(IEC C1galt1−/−) mice specific for intestinal epithelial cells. All the animals with deletion of 
C1galt1 in intestinal epithelial cells developed distal colon inflammation at 12 weeks of age. 
Deletion of C1galt in epithelial cells was also induced in adult animals and, 10 days later, the 
development of colitis was also observed [23].
e. MDR1a−/− mice
The multiple drug resistance gene (MDR1) codes the multiple drug carrier (P-glycoprotein) 
in intestinal epithelial cells. Around 25% of FVB mice with the gene MDR1a “deactivated” 
developed colitis at 1 year of age [24]. In the Japanese population, the MDR1 gene was related 
to susceptibility to late onset of UC [25]. To obtain FVB.mdr1a−/− mice, FVB control mice 
and mdr1a−/− mice were bred and maintained in the SPF facility. Mdr 1a−/− mice had been 
backcrossed onto the FVB strain for at least seven generations for models obtained at Taconic 
Farms [24].
f.  Ire1 α flox/flox-Villin-Cre mice
Inositol requiring enzyme 1α (IRE1 α) acts as a major stress sensor. The Villin-Cre transgenic 
mice expressing Cre recombinase specifically in intestinal epithelium is currently available. 
Floxed mice (Ire1 α flox/flox), in which the 121-nucleotide exon 2 of the Ern1 (i.e. Ire1 α) allele 
was flanked with two loxP recombination sites. Intestinal epithelia-specific Ire1 α knock-out 
mice (Ire1 α flox/flox-Villin-Cre) were produced therefore, by intercrossing the Ire1 α flox/flox mice 
with Villin-Cre mice. Animals without IRE1 α develop spontaneous colitis and are character-
ized by the loss of goblet cells, which causes the intestinal epithelial barrier to become non-
functional [26].
g. NEMOIEC−KO mice
Animals with deactivation of nuclear factor-kappa B (NF-ĸβ) binding in intestinal epithe-
lial cells, through conditional ablation of NEMO or both IKK1 (IKKa) and IKK2 (IKKb)—
IKK subunits essential for NF-ĸβ activation, have an exacerbated response to luminal 
microbiota, which leads to the development of colitis with apoptosis of epithelial cells at 
the age of 6 weeks. To investigate the function of NF-ĸβ signaling in the gut epithelium 
in vivo, this was generated in mice lacking NEMO specifically in intestinal epithelial cells 
(NEMOIEC−KO mice) by crossing mice carrying loxP-flanked (floxed, FL) NEMO (Ikbkg) 
alleles with Villin-Cre transgenics. These experiments were performed using mice back-
crossed into the C57BL/6 genetic background for at least five generations. They were used 
as wild-type controls. The mice used were housed in individually ventilated cage sys-
tems, in either specific pathogen-free or conventional animal facilities [27, 28]. Therefore, 
regardless of the immune system, intestinal cells clearly provide protection against bacte-
rial pathogens of the microbiota [18].
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2.1.1. Transgenic animal models expressing colitis through modulation of immune regulatory 
agents
Mice with several genetic disorders associated with immune regulation were examined, 
revealing the development of colitis that was related to different substances [18]. These models 
with genetic modifications that affect immune regulation and trigger IBD are discussed below.
a. Type II receptor for TGF-β or SMAD4 absence
The transforming growth factor-beta 1 (TGF-β1) acts both in immune regulation and in the 
differentiation of regulatory T cells. Transgenic animals with dominant-negative mutant 
TGF-β type II receptor in specific CD4+ T cells showed spontaneous inflammation at around 
3–4 months of age, and there was increased expression of Th1 and Th2 cytokines in several 
body organs such as colon, liver, stomach, duodenum, pancreas and kidney. These animals 
were created by using DNA microinjection into (C57BL/6xC3H) F1 fertilized oocytes, which 
results in six transgene-positive mice. All pups in the experimental cycle appeared normal 
at 2 weeks of age, but three died between 2 and 4 weeks of age. Three remaining transgene-
positive mice appeared healthy and were bred; their progeny was further used to identify 
transgenic lines expressing a functional dominant-negative TGF-β receptor type II [29].
Animals with specific deletion of type II receptor for TGF-β in typical dendritic cells devel-
oped several inflammations, including colitis. Thus, B6.129S6-Tgfbr2tm1hlm mice, carrying 
homozygous loxP site insertion flanking exon 2 of Tgfbr2 gene is currently available and 
obtainable from the National Cancer Institute (Frederick, MD) mouse repository (strain 
01XN5) and other laboratories. CD11c-Cre transgenic mice (B6.Cg-Tg(Itgax-cre)1-1Reiz/J), 
OT-II transgenic mice (B6.Cg-Tg(TcraTcrb)425Cbn/J), Rag1−/− (B6.129S7-Rag1tm1Mom/J) and 
wild-type C57BL/6 J are all obtainable by researchers. The mouse model with CD-specific 
Tgfbr2 deletion highlights the critical importance of TGF-β signaling in CDs in the mainte-
nance of immune homeostasis and in the prevention of autoimmunity [30].
SMAD4 acts as a mediator in intracellular signaling of TGF-β. To inactivate specifically 
Smad4 in T cells, it was necessary to cross mice with a transgene encoding a Cre-recombinase 
driven by the Lck promoter (Smad4co/co; Lck-Cre) or the CD4 promoter (Smad4co/co; 
CD4-Cre) with the strain carrying the Smad4 conditional allele (Smad4co/co). Mice with-
out SMAD4 in specific T cells and those without SMAD4 in CD4+ T cells had inflammation 
through the entire gastrointestinal tract at 3 months of age [31].
b. Mutations affecting the interleukin receptor (IL-2)
Interleukin-2 (IL-2) is related to activated-induced cell death and to the triggering of regula-
tory T cells function. Deficient IL-2 mice develop spontaneous autoimmune colitis, gastri-
tis, hepatitis, pneumonia, pancreatitis, nephritis and hemolytic anemia [32]. Janus tyrosine 
kinase 3 (JAK 3) acts as a transducer of interleukin-2 receptor common gamma chain. 
Deficiency of JAK 3 led to the spontaneous development of colitis in mice [33]. The animal 
model that uses IL-2 is characterized by association of colitis with the autoimmune mecha-
nism, which was demonstrated in the spontaneous onset of colitis without the presence of 
microorganisms [34].
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Similarly, IL-10 is a regulatory cytokine with IBD susceptibility genes not only in adults but 
also in children [35–37]. IL-10 deficient mice develop spontaneous colitis [38]. Mice with 
deleted CRF2-4, a component of the IL-10 receptor, develop splenomegaly and disorders such 
as chronic colitis [39].
c. Mice with T cell-related mutations
The T cell receptor (TCR) is essential for the recognition of antigens by T cells. Approximately 
60% of mice without TCR α, TCR component, developed Th2-mediated spontaneous colitis. 
The animals used in this study were produced by crossing TCR β × mutant mice with TCR 
mutant mice, and generated TCR β × gamma double mutant mice, which are deficient both in 
αβ and γ cells. By mutating, the recombination-activating gene RAG-1 mice totally deficient 
in mature T and B lymphocytes were produced [40].
The transcription factor, signal transducer and activator of transcription 3 (STAT3) acts in the 
control of various innate immune responses such as differentiation of Th17 cells and epithelial 
renovation. Its gene is susceptible to UC and CD [35, 36]. Animals with intestinal epithelial 
cells deficient in STAT3 developed spontaneous colitis. In response to inflammatory stimuli, 
LysMcre/Statflox/− mice develop enterocolitis even though they produce more IL-10 than nor-
mal animals in the same condition. To disrupt the Stat3 gene specifically in macrophages and 
neutrophils, two types of animals were crossed, mice in which the Stat3 gene is flanked by 
two loxP sites (Stat3flox/flox) and the other mouse in which the Cre cDNA is inserted into the 
lysozyme M gene by a knock-in approach (LysMcre mice) [41].
STAT4 is a transcription signal transducer and activator factor that acts in the development 
of Th1 cells. Its gene was considered susceptible to UC in individuals with white skin [42]. 
Transgenic mice with super expression of STAT4 when immunized with 2,4- dinitrophenol-
keyhole limpet hemocyanin/Complete Freund’s Adjuvant (DNP-KLH/CFA) to activate the 
cytomegalovirus (CMV) developed transmural colitis. The murine STAT-4 cDNA was cloned 
downstream of the CMV promoter into the pcDNA3.1 expression vector (Invitrogen, San 
Diego, CA) yielding the pcDNA3.1S4 vector. A 3.6-kp NruI/PvuII fragment of pcDNA3.1S4 
containing the STAT-4 expression cassette was microinjected into pronuclei of fertilized eggs 
of FVB/NHSD mice. Mice were maintained under specific pathogen-free conditions in iso-
lated cages [43].
d. Gαi2−/− mice
Gαi2 signal transduction proteins participate in a wide signaling system. Mice that lack 
Gαi2 proteins showed dysfunctions related to T cells and developed colitis when they were 
3–4 weeks old and colorectal cancer at approximately 3–4 months of age. Gαi2-deficient 
(Gαi2−/−) mice on a 129SvEv X C57BL/6 background (backcrossed four or five generations into 
129SvEv and then intercrossed) and on a pure 129SvEv background were used [44–46].
e. A20−/−mice
A20 is an enzyme related to ubiquitin, which in turn is associated to NF-ĸβ1 activation. It acts 
in the prevention of tissue destruction and inflammation mediated by innate immune cells, in 
addition to regulating skin differentiation. To study the functions of A20 in vivo, A20-deficient 
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(A20−/−) was generated by gene targeting. Rodents that lack this enzyme developed inflamma-
tion in various organs, including bowel, when they were 3–6 weeks olds [47].
f. T-bet−/− mice
T-bet is a transcription factor that regulates the differentiation of T cells into Th1 cells. To 
investigate whether the T-bet’s protective function is linked to innate immunity, the T-bet−/− 
mouse developed on the RAG2−/− background was examined. The mice experimental model 
that lacked the T-bet factor showed no colitis. On the other hand, a new mouse model through 
which animals without T-bet were crossed with RAG2 mice lacking T and B cells showed the 
development of colitis similar to what occurs in UC at 4 weeks of age, therefore, T-bet expres-
sion protects against colitis and T-bet−/− × RAG2−/− mice develop spontaneous colitis [48].
g. TNF ΔARE mice
TNF-α is related to the onset of CD, because of the development of spontaneous inflamma-
tion in the ileum of mice with increased TNF-α activity [49]. Animals with intrinsic defect 
related to post-transcriptional regulation of TNF mRNA (TNF ΔARE rat model) developed 
inflammation, especially in the terminal ileum and subsequently in the proximal colon [50, 
51]. To develop TNFΔARE mice, a 69bp deletion encompassing TNF ARE was conducted 
in embryonic stem cells in conjunction with the neomycin resistance marker (neo) flanked 
by loxP sequences. The excision of the neon gene and generation of TNFΔARE rat lines was 
due to the transient expression of the Cre recombinase in fertilized oocytes from the previ-
ously mentioned mice. The TNFΔARE homozygous mice developed early pathologies and 
also had a short shelf life. To reverse this problem, the effects of the TNFΔARE mutation on 
TNF biosynthesis were investigated in TNFΔARE/− hemizygous mice generated by the cross-
ing of TNFΔARE/+ to TNFΔARE/− mice. The use of hemizygous TNFΔARE/− mice made it 
possible to investigate the regulatory role of the ARE element in a monoallelic system without 
the interference of a wild type TNF allele in the generation of TNF. So, a defective function 
of ARE may be etiopathogenic for the development of analogous human pathologies, in this 
case, Crohn’s-like inflammatory bowel disease.
h. SRα/IL-7 mice
IL-7 has an important role in the homeostasis of T cells, and the gene linked to the IL-7 recep-
tor was related to UC [35, 36]. To study the IL-7 role, it was critical to develop the model SRα/
IL-7 transgenic mice using 2.1 kb SRα/lL-7 DNA fragment that was linearized by AatH and 
ApaU digestion. Microinjection into the pronuclei of fertilized eggs of C57BL/6 J mice was 
performed with ~103 copies of the SRα/lL-7 DNA fragment according to the standard pro-
cedure [52]. Rodents with super expression of IL-7 developed spontaneous colitis at about 
4–12 weeks of age [53].
i. Double-KO mice deficient in both Gpx1 and Gpx2 gene expression
Activation of endoplasmic reticulum (ER) stress responses of intestinal epithelial cells to the 
metabolic by products of bacteria in the intestinal lumen is necessary for intestinal homeosta-
sis and prevention of chronic inflammation [18]. The glutathione peroxidase (GPX) enzyme is 
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selenium-dependent and can reduce a broad range of hydroperoxides. The inflammatory pro-
cess is associated with increased lipid peroxidation, and hydroperoxide appears to mediate 
IBD-related symptoms. To clarify the role of GPX in the intestinal epithelial cells, a homozy-
gous double-KO mice with interruption in the expression of Gpx1 and Gpx2 genes was gen-
erated. These animals have signs and symptoms related to inflammatory bowel disease. The 
Ye-Shih Ho (Wayne State University, Detroit, MI) generated Gpx1-KO mice, as C57BL/6 J and 
129Sv/J hybrids. Likewise, the generation of Gpx2-KO mice as B6 and 129S3 hybrids occurred 
at the City of Hope (COH; Duarte, CA) Transgenic Mouse Core. These mice were housed at 
the COH Animal Resources Center in ventilated cage racks. So, it was possible to verify that 
mice deficient in Gpx1 and GPX2 developed spontaneous colitis and ileitis GPX2 at about 
3 weeks of age [54].
The transcription factor XBP1 is involved in the response to ER stress. XBP1 was related to 
CD and UC. To understand the function of this factor, Xbp1 exon 2 was almost completely 
disrupted in the intestinal tissue (small intestine and colon). Mice with specific deletion of this 
factor in intestinal epithelial cells developed spontaneous ileitis due to the lack of Paneth cells 
that secrete protective cells [55].
2.2. Adoptive transfer model of colitis
The referred methodology induces intestinal inflammation through selective transfer of cer-
tain types of immune cells in animals with impaired immune systems (RAG-1 knockout and 
RAG-2 knockout and SCID pigs). The study based on these models allows the investigation 
of immune factors, particularly the role of pathogenic T cells and T cell-mediated colitis on 
mucosal inflammation [18] (Table 2).
a. CD4+ CD45RBhi model
The transfer of T CD4+ cells with high levels of protein CD45RB to mice deficient in T cells 
(RAG−/− or SCID) is the transfer methodology most commonly used to induce colitis, and it 
increases intestinal inflammation approximately 5–10 weeks after the transfer [56–58]. This 
method causes an inflammation similar to that of models that use chemical agents and is 
characterized by hyperplasia and inflammation in the colon, generally causing the death of 
the animal [59].
Models Main results References
CD4 + CD45RBhi Intestinal inflammation with Th1 responses to antigens of 
bacteria in the lumen
[56–61]
SheLAg-specific CD4+ T cells Colitis caused by one single bacterial antigen [62]
Hsp60-specific CD8+ T cells Severe inflammation in the mucosa of the small intestine, 
regardless of the animal’s microbiota
[63]
Table 2. Adoptive transfer models of intestinal inflammation.
Use of Animal Models in the Study of Colitis
http://dx.doi.org/10.5772/intechopen.75608
221
This model of cell transfer triggers Th1 responses to bacteria in the lumen [60]. After cell trans-
fer, naive T cells react to antigens of the luminal bacteria and expand rapidly in the lymph 
nodes and colon mucosa, becoming oligoclonal. The presence of pathogenic effector Th1 cells 
was possible due to the absence of regulatory T cells [18, 61].
b. SheLAg-specific CD4+ T cells
H. hepaticus Ag (SHelAg)-specific CD4+ Th1 clones transfer the disease to RAG1 knockout 
mice deficient in T cells and infected with a pathogenic bacterium (H. hepaticus) causing coli-
tis between 7 and 8 weeks after the transfer, while the non-infected receptors did not develop 
colitis. It is inferred, therefore, that pathogenic T cells that respond to a single bacterial anti-
gen may lead to the development of colitis [62].
c. Hsp60-specific CD8+ T cells
In general, heat shock proteins (HSP) are antigens considered potential targets to autoim-
mune disease. Then, the transfer of CD8+ T cells responsive to HSP60 for immunodeficient 
animals can trigger severe inflammation in the mucosa of the small intestine regardless of the 
animal’s microbiota [63].
The severity of inflammation by adoptive transfer depends on the donor animal, as well as to 
the recipient [64, 65]. A study aimed to protocol standardization found that Balb/SCID mice 
develop a more severe and faster type of colitis C57BL/6 RAG-1−/− mice [66].
2.3. Models of spontaneous colitis
These models concern both the animals that develop spontaneous inflammation in the mucosa 
and those with inadequate mucosal immune response due to defect or genetic modification [56]. 
Spontaneous models are of great interest for the study of intestinal inflammation since, as in dis-
ease in humans, there is no external manipulation. The murine model C3H/HeJBir, for example, 
is characterized by chronic inflammation in the colon and in the cecal region [67] (Table 3).
a. C3H/HeJBir mouse model
Because of the occurrence of soft, light-colored feces and/or secondary perianal ulceration, 
and histological evidence of colitis, without pathogens, mice of the C3H/HeJ strain are likely 
to have a genetic predisposition to develop a form of IBD, with perianal ulceration, it has the 
pedigree to generate a “high-susceptibility” substrain, C3H/HeJBir, with a high incidence of 
spontaneous colitis [68].
Models Main results References
C3H/HeJBir Chronic inflammation in the colon and cecal region similar to CD [67, 69]
SAMP1/YitFc Severe inflammation in the terminal ileum, similar to CD [70, 71]
Table 3. Models of spontaneous colitis.
Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy222
The wounds observed in this mouse model occur in the ileocecal region and the colon. Clinical 
manifestations begin at 3–4 weeks of age and last up to 10–12 weeks of age, approximately. 
The characteristics of the colitis developed by this methodology are similar to those of CD 
[17, 69].
b. SAMP1/YitFc model
Investigation of the mechanisms of CD can be based on the model that uses SAMP1/YitFc 
mice, where there is spontaneous and/or severe inflammation of the terminal segment of 
the ileum, which is the primary site of the wounds in CD, this disease model in animals 
also resembles human CD with regard to histologic features [15, 70, 71]. For the purposes 
of these experiments, a colony of SAMP1/Yit mice in a barrier facility at the University 
of Virginia was established from animals provided by Yakult Central Institute for 
Microbiological Research (Tokyo, Japan). The SAMP1/Yit (H-2k) mouse strain was origi-
nally derived from AKR mice (original parents purchased from The Jackson Laboratories, 
Bar Harbor, Maine, USA) [70]. The findings from the adoptive transfer research have 
made it possible to infer that CD4+ T cells that generate a Th1-like cytokine profile, for 
example, IFN-γ and TNF, act as mediators of intestinal inflammation observed in SAMP1/
Yit mice.
2.4. Chemically induced models of intestinal inflammation
Experimental models of colitis induced by chemical agents are used in the analysis of patho-
logical mechanisms of IBD as well as the development of therapeutic agents. The referred 
method facilitates the induction of colitis. Some chemicals, such as dextran sodium sulfate 
(DSS) and trinitrobenzene sulfonic acid (TNBS) are the most commonly used substances. 
Models with such agents have been used for more than 20 years for the investigation and 
circumstances that affect the development of IBD [16] (Table 4).
Induction of inflammation by chemical agents can cause disorders in the barrier of the intes-
tinal mucosa and/or cause hapten-induced hypersensitivity reactions [18]. Several factors are 
related to the magnitude of the onset of colitis in models induced by chemical substances. 
Although these models do not have the complexity of human IBD, they can contribute to the 
study of the processes involved in the control of the disease [72].
Models Main results References
DSS Diarrhea with bleeding, ulcerations and infiltration of granulocytes. Some 
characteristics are similar to UC in humans
[73, 74]
TBNS Transmural colitis that resembles CD [80–82]
DNBS Extensive tissue damage and acute inflammatory process similar characteristics 
to CD
[80]
Oxazolone Inflammation of the distal colon with clinical similarities to UC [74]
Table 4. Chemically induced models of intestinal inflammation.
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a. DSS approach
DSS methodology has been used to induce colitis since 1985 because the disease induced is 
very similar to the human disease [73]. Its mechanism of action is related to direct epithelial 
toxicity, which impacts on the epithelial barrier of the intestinal mucosa [18]. In the referred 
methodology, the substance is diluted in water for animal drinking, for a period ranging from 
5 to 7 days. The inflammation induced by DSS has characteristics similar to diarrhea with 
bleeding, ulcerations and granulocyte infiltration. Dysplasia often occurs during the chronic 
stage of the inflammation, which is very similar to ulcerative colitis in humans [16, 74].
The inflammatory immune response occurs immediately after disturbance of the intestinal 
epithelium, due to contact of the antigens in the lumen with the immune cells of the mucosa 
and submucosa areas [72].
Acute and chronic forms of the disease can be induced, according to the doses and treatment 
cycles. DSS was also used to induce IBD in transgenic and immunodeficient animals, and 
most of them are prone to intestinal inflammation. Also, the symptoms and the pathology are 
more severe with the association of this chemical agent [18]. DSS-induced colitis is frequently 
used in studies on innate immune processes involved in the onset of IBD and also in restoring 
the intestinal barrier integrity [72].
b. TBNS
In hapten-induced colitis, the TNBS substances dinitrobenzene sulfonic acid (DNBS) or oxa-
zolone dissolved in ethanol can be administered rectally. The type of response triggered (Th1/
Th2) will depend on the hapten selected, as well as on the susceptibility of the animal, and 
route of administration of the chemical agent. Ethanol is used to disrupt the barrier of the 
intestinal mucosa, while the agent (TNBS, DNBS or oxazolone) is associated with an autolo-
gous protein or microbiota byproducts, becoming immunogenic, and triggering the interac-
tion of specific antigens and cells of the immune system [18, 75, 76]. The IBD models induced 
by hapten, similar to those that use DSS, can also be applied in transgenic and immunodefi-
cient animals, as well as in those susceptible to immune-mediated colitis [77–80].
In the beginning of the experiment with TNBS-induced model, one single dose can be admin-
istered, resulting in acute inflammation, with Th1 response occurring in 2–3 days. Initial sen-
sitization with TNBS can be done by rectal application or via skin, and another administration 
must be performed 6 days later for the development of delayed hypersensitivity response to 
TNBS-haptenized colonic proteins [81].
TNBS is administered rectally with ethanol, amidst haptenization of the proteins from the 
microbiota and the emergence of T CD4+ cells. The severity and the extent of the inflamma-
tion depend on genetic factors inherent in the animals and the presence or absence of bacteria 
that activate T cells [71]. T CD4 + cells are strongly related to Th1-mediated immune responses 
through IL-12 cytokines, culminating in transmural colitis similar to CD [80, 82].
The IBD model that uses DNBS is similar to the one induced by TNBS, because there is exten-
sive tissue damage and acute inflammatory process. Also, as it occurs in CD, it depends on T 
CD4+ cells [80].
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Oxazolone is generally administered after subcutaneous pre-sensitization (abdomen), which 
stimulates greater formation of Th2 cytokines and inflammation of the distal colon resem-
bling ulcerative colitis [74].
Like TBNS, oxazolone is also administered rectally. Acute inflammation of the distal mucosa 
and submucosa generally involves ulcers and infiltrations of neutrophils, macrophages and 
lymphocytes. The type of response triggered depends on the dose of the substance admin-
istered. Overall, this model is useful for the investigation of specific characteristics of the 
inflammatory process in chronic IBD [72].
Type of induction Characteristics Limitations Advantages References
Genetic modification Occurs by gene 
modification; 
overexpression or absence 
of a non-functional 
gene/protein of interest 
in all cell types or in 
a particular cell type, 
acting on the promotion 
of inflammation by 
impairment of epithelial 
barrier function and 
bacterial sensing, innate 
immune signaling, 
immune regulation, and 
stress response signaling
It analyzes the 
pathogenesis of IBD 
in general
It tests the efficacy 
of new drugs in a 
lesser than other 
approached in a 
preclinical studies
Investigation of 
certain inflammatory 
mediators and cellular 
interactions present in 
intestinal inflammation
Study and better 
understanding of 
the complexity of 
multiple genes and 
the different types 
of polymorphisms 
observed in patients
[14, 18, 19]
Chemical agents It induces intestinal 
inflammation by acting 
on the disturbance of 
the mucosal barrier, 
epithelial and/or by 
triggering reactions of 
hypersensitivity by hapten
It is not sufficient 
to understand and 
characterize the 
inflammatory and 
immunological 
processes involved 
in intestinal 
inflammation and the 
pathogenesis of IBD
It encompasses 
methodologies that 
are considered easy 
to induce, and its 
simplicity allows it 
to be used in several 
experimental protocols
[14, 18]
Cell transfer It induces intestinal 
inflammation in an 
immunodeficient host 
through the selective 
transfer of immune cell 
types
It uses a factor 
(adaptive immunity) 
that is not the only 
necessary requirement 
for the development 
of IBD
Investigation of specific 
route abnormalities 
and immune gut 
inflammation
To study the role of 
regulatory T cells 
and mucosal immune 
regulation
[14, 18]
Spontaneous 
inflammation
The crossing of two types 
of rodents with different 
genetic contexts provided 
models that present 
spontaneous intestinal 
inflammation, without 
induced genetic alterations 
or interventions
Difficulty related to 
the acquisition of 
models (availability)
Because there is no 
intervention, it mimics 
the complex and 
multifactorial aspects 
that encompass the 
disease in humans
[14, 18, 66]
Table 5. Comparative presentation of the various methods of colitis induction.
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Table 5 shows a comparative presentation of the various ways colitis disease is induced as 
discussed herein. Each of the several models discussed here have similarities with human IBD, 
and offer advantages for the study of certain aspects involved in the pathogenesis of the dis-
ease. Induction by chemical agents is often used widely by researchers mainly because it is 
easier, although it does not contribute to the elucidation of inflammatory and immunological 
processes involved in IBD [14, 18]. Genetic modification allows the study of specific aspects 
present in IBD; however, such form of induction does not allow to analyze the disease in a 
global way, and contributes less to the test of efficacy of new drugs [14, 18, 19]. Cellular trans-
fer helps to study specific issues, contributing to the investigation of the role of regulatory T 
cells and mucosal immune regulation, but adaptive immunity alone does not act in the onset 
of IBD [14, 18]. The spine development of colitis reproduces the disease as in humans (since 
there is no intervention), allowing the investigation of complex and multifactor situations that 
are present in the disease, nevertheless, there is a low availability of models reported in the 
literature [14, 18, 66].
3. Final considerations
The animal models described here can contribute to the understanding of various mecha-
nisms involved in IBD, as well as to the development of new drugs to improve the treat-
ment. It would be extremely difficult to carry out these investigations and experimentation 
in humans. However, due to a good number of animal models available for this disease, care 
should be taken in the selection of animal/model choice. Investigators should take into con-
sideration the purpose of their study, for example, the type of compound to be tested and/or 
pathophysiological mechanisms to be investigated.
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